Literature DB >> 25411181

Development of a multiple-locus variable-number tandem-repeat typing scheme for genetic fingerprinting of Burkholderia cenocepacia and application to nationwide epidemiological analysis.

Christine Segonds1, Michelle Thouverez2, Antoine Barthe3, Nadège Bossuet-Greif4, Lenka Tisseyre4, Patrick Plésiat2, Gilles Vergnaud5, Gérard Chabanon6, Christine Pourcel7.   

Abstract

Organisms of the Burkholderia cepacia complex are especially important pathogens in cystic fibrosis (CF), with a propensity for patient-to-patient spread and long-term respiratory colonization. B. cenocepacia and Burkholderia multivorans account for the majority of infections in CF, and major epidemic clones have been recognized throughout the world. The aim of the present study was to develop and evaluate a multilocus variable-number tandem-repeat (VNTR) analysis (MLVA) scheme for B. cenocepacia. Potential VNTR loci were identified upon analysis of the annotated genome sequences of B. cenocepacia strains AU1054, J2315, and MCO-3, and 10 of them were selected on the basis of polymorphisms and size. A collection of 100 B. cenocepacia strains, including epidemiologically related and unrelated strains, as well as representatives of the major epidemic lineages, was used to evaluate typeability, epidemiological concordance, and the discriminatory power of MLVA-10 compared with those of pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Longitudinal stability was assessed by testing 39 successive isolates from 14 patients. Typeability ranged from 0.91 to 1, except for that of one marker, which was not amplified in 53% of the B. cenocepacia IIIA strains. The MLVA types were shown to be stable in chronically colonized patients and within outbreak-related strains, with excellent epidemiological concordance. Epidemic and/or globally distributed lineages (epidemic Edinburgh-Toronto electrophoretic type 12 [ET-12], sequence type 32 [ST-32], ST-122, ST-234, and ST-241) were successfully identified. Conversely, the discriminatory power of MLVA was lower than that of PFGE or MLST, although PFGE variations within the epidemic lineages sometimes masked their genetic relatedness. In conclusion, MLVA represents a promising cost-effective first-line tool in B. cenocepacia surveillance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25411181      PMCID: PMC4298531          DOI: 10.1128/JCM.02473-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.

Authors:  J R Govan; P H Brown; J Maddison; C J Doherty; J W Nelson; M Dodd; A P Greening; A K Webb
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

2.  Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis.

Authors:  J S Chen; K A Witzmann; T Spilker; R J Fink; J J LiPuma
Journal:  J Pediatr       Date:  2001-11       Impact factor: 4.406

3.  Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers.

Authors:  J J LiPuma; J E Mortensen; S E Dasen; T D Edlind; D V Schidlow; J L Burns; T L Stull
Journal:  J Pediatr       Date:  1988-11       Impact factor: 4.406

4.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis.

Authors:  Tom Coenye; John J LiPuma
Journal:  J Infect Dis       Date:  2002-04-23       Impact factor: 5.226

6.  Identification by subtractive hybridization of a novel insertion element specific for two widespread Burkholderia cepacia genomovar III strains.

Authors:  Lixia Liu; Theodore Spilker; Tom Coenye; John J LiPuma
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

7.  Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center.

Authors:  Graziana Manno; Claudia Dalmastri; Silvia Tabacchioni; Peter Vandamme; Renata Lorini; Laura Minicucci; Luca Romano; Alessandro Giannattasio; Luigi Chiarini; Annamaria Bevivino
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  The Burkholderia cepacia epidemic strain marker is part of a novel genomic island encoding both virulence and metabolism-associated genes in Burkholderia cenocepacia.

Authors:  Adam Baldwin; Pamela A Sokol; Julian Parkhill; Eshwar Mahenthiralingam
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

10.  Characterization of PCR-ribotyping for Burkholderia (Pseudomonas) cepacia.

Authors:  S E Dasen; J J LiPuma; J R Kostman; T L Stull
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more
  1 in total

Review 1.  Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches.

Authors:  Viola C Scoffone; Laurent R Chiarelli; Gabriele Trespidi; Massimo Mentasti; Giovanna Riccardi; Silvia Buroni
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.